Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 2 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
6 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

Olanzapine improves weight in adult outpatients with anorexia nervosa

12 Feb 2019

Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.

“Nevertheless, the finding on weight is notable, as achieving change in weight is notoriously challenging in this disorder,” the authors noted.

This randomized double-blind placebo-controlled trial conducted at five sites in North America assessed the benefits of olanzapine vs placebo for adult outpatients with anorexia nervosa.

A total of 152 participants (96 percent women; mean body mass index [BMI], 16.7 kg/m2) were randomly assigned in a 1:1 ratio to receive either olanzapine (n=75) or placebo (n=77). They were observed weekly for a 16-week period. The primary outcome measures were rates of change in body weight and change in obsessionality, assessed with the Yale-Brown Obsessive-Compulsive Scale (YBOCS).

Findings showed a statistically significant treatment-by-time interaction, which suggested that the increase in BMI over time was higher in patients in the olanzapine group (0.259 vs 0.095 per month) than in those in the placebo group.

No significant between-group difference was observed in change in the YBOCS obsessions subscale score over time (–0.325 vs –0.017 points per month). In addition, no significant between-group differences were seen in the frequency of abnormalities on blood tests assessing potential metabolic disturbances.

A small study in 2011 reported that olanzapine was more effective than placebo and was generally well tolerated by outpatients with anorexia nervosa. [Psychol Med 2011;41:2177-2182]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 2 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
6 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.